FIND A DERMWe Put MIRVASO Gel to the Test
Facial redness of rosacea was significantly diminished in clinical studies
In clinical trials, subjects who used MIRVASO® (brimonidine) topical gel, 0.33%* saw their redness diminished for up to 12 hours. And for many, redness began to fade fast—often in as little as 30 minutes. As with any treatment, results can vary.
During clinical trials, 1210 participants were exposed to MIRVASO Gel. A total of 833 participants were treated for persistent facial redness of rosacea; 330 of those were treated once daily for 29 days in vehicle-controlled trials.
These photos show actual results from the two 4-week, phase 3, multicenter, randomized, vehicle-controlled studies evaluating the efficacy and safety of MIRVASO Gel. Primary endpoint†: Subjects and researchers were asked to grade the improvement they saw at hours 3, 6, 9, and 12 following application. On day 29 of the trials, 2-grade improvement was observed with MIRVASO Gel vs vehicle gel at hour 3 (28% vs 10%), at hour 6 (28% vs 9%), at hour 9 (22% vs 10%), and at hour 12 (22% vs 9%). Secondary endpoint†: Redness was visibly reduced in as early as 30 minutes for 28% of study participants (vs 6% of subjects using vehicle gel).
MIRVASO Gel continued to reduce redness, month after month‡
In a 1-year clinical trial, subjects who used MIRVASO Gel daily for at least 12 months had consistent results—from day 1 through day 365.‡ The most common side effects were flushing (10%), erythema (8%), worsening of rosacea (5%), nasopharyngitis (5%), skin burning sensation (4%), increased intraocular pressure (4%), and headache (4%).
| Study Participant #8076-001 | |
Baseline
|
|
| Study Participant #8076-003 | |
Baseline
|
|
| Study Participant #8139-010 | |
Baseline
|
|
| Study Participant #8076-005 | |
Baseline
|
|
| Study Participant #8057-024 | |
Baseline
|
|
Actual results with MIRVASO Gel from 4-week clinical studies. Individual results may vary.
The safety and efficacy of MIRVASO Gel was evaluated in 2 identical, randomized, vehicle-controlled trials with 553 subjects aged 18 years and older. Study participants were randomized 1:1 to receive either MIRVASO Gel or vehicle gel once daily for 4 weeks. The primary endpoint for both studies was 2-grade composite success at hours 3, 6, 9, and 12 on day 29. The secondary endpoint was 1-grade composite success at 30 minutes on day 1. Composite success was defined as improvement on both the Clinician Erythema Assessment and Patient Self-Assessment.
Important Safety Information
Indication: MIRVASO® (brimonidine) topical gel, 0.33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: MIRVASO Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. MIRVASO Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Gel by children have been reported. Keep MIRVASO Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.
†The safety and efficacy of MIRVASO Gel was evaluated in 2 identical, randomized, vehicle-controlled trials with 553 subjects aged 18 years and older. Study participants were randomized 1:1 to receive either MIRVASO Gel or vehicle gel once daily for 4 weeks. The primary endpoint for both studies was 2-grade composite success at hours 3, 6, 9, and 12 on day 29. The secondary endpoint was 1-grade composite success at 30 minutes on day 1. Composite success was defined as improvement on both the Clinician Erythema Assessment and Patient Self-Assessment.
‡The long-term safety and efficacy of MIRVASO Gel was evaluated in a one-year, open-label, non-comparative study in 276 subjects with moderate to severe facial redness of rosacea who used MIRVASO Gel once daily for at least 12 months.
All trademarks are the property of their respective owners.